Marcelo Vailati Negrao, MD

Peer-Reviewed Articles

1. Araujo HA, Pechuan-Jorge X, Zhou T, Do MT, Hu X, Rojas Alvarez FR, Salvatierra ME, Ibarguen HP, Lee R, Raghulan R, Shah H, Moreno Ayala MA, Chen K, Tovbis Shifrin N, Wu S, Solis Soto LM, Negrao MV, Gibbons DL, Hong DS, Roth JA, Heymach JV, Zhang J, Jiang J, Singh M, Smith JAM, Quintana E, Skoulidis F. Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC. Cancer Discov, 2025. e-Pub 2025. PMID: 38975897.
2. Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ. Updated Overall Survival Analysis From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. J Clin Oncol:101200JCO2502023, 2025. e-Pub 2025. PMID: 41109959.
3. Riely GJ, Ahn MJ, Clarke JM, Dagogo-Jack I, Esper R, Felip E, Gelsomino F, Goldman JW, Hussein M, Johnson M, Marrone KA, Morgensztern D, Nadal E, Negrao MV, Offin M, Provencio M, Ramalingam SS, Roof L, Sanborn RE, Smit EF, Tsao A, Usari T, Alcasid A, Wilner K, Tonkovyd S, Zhang X, Johnson BE. Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report. J Thorac Oncol 20(10):1538-1547, 2025. e-Pub 2025. PMID: 40480428.
4. Di Federico A, Wang K, Chen MF, Barsouk AA, Pagliaro A, Chen LN, Ogliari FR, Stockhammer P, Thawani R, Raslan S, Gariazzo E, Fusco F, Hambelton GM, Citarella F, Meyer D, Aldea M, De Giglio A, Alessi JV, Pecci F, Gelsomino F, Corassa M, Vokes NI, Wang X, de Biase D, Abu Rous F, Areesawangkit P, Elghawy O, Cortellini A, Metro G, Ferrara R, Awad MM, Pabani A, Murray JC, Cappuzzo F, Garassino MC, Dagogo-Jack I, Riely G, Grant M, Herzberg BO, Ardizzoni A, Planchard D, Johnson BE, Langer CJ, Offin M, Negrao MV, Ricciuti B. First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF(V600E)-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study. Lancet Oncol 26(10):1357-1369, 2025. e-Pub 2025. PMID: 41038185.
5. Pecci F, Li H, Di Federico A, Wu J, Chen H, Gariazzo E, Mantuano F, Garbo E, Aldea M, Santo V, Gibbons D, Tran H, Paoloni F, Rossato de Almeida G, Metro G, De Giglio A, Gelsomino F, Wang X, Tiseo M, Rotow J, Ardizzoni A, Lee JJ, Awad MM, Addeo A, Hong L, Negrao MV, Janne PA, Heymach JV, Zhang J, Ricciuti B, Le X. First-line MET tyrosine kinase inhibitors versus immunotherapy +/- chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC. Clin Cancer Res, 2025. e-Pub 2025. PMID: 40864503.
6. Zhang B, Shah KB, Parma M, Wang K, Singhi EK, Lewis W, Rivera M, Altan M, Pozadzides J, Le X, Vokes N, Fossella F, O'Brien B, Wang C, Tom MC, Beckham T, Swanson T, Bronk J, Lin SH, Vega MF, Jacome J, Halliday A, Negrao M, Zhang J, Gibbons DL, Heymach JV, Byers LA, Gay CM. Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report. J Thorac Oncol 20(8):1131-1138, 2025. e-Pub 2025. PMID: 40126456.
7. Mitchell KG, Lee Y, Deboever N, Negrao MV, Tran HT, Parra E, Byers L, Reuben A, Federico L, Bernatchez C, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, McGrail DJ, Sepesi B, Haymaker CL. Intratumoral neutrophil-to-lymphocyte ratio is mirrored by circulating neutrophil-to-lymphocyte ratio in non-small cell lung cancer. J Immunother Cancer 13(6), 2025. e-Pub 2025. PMID: 40555561.
8. Heeke S, Gandhi S, Tran HT, Lam VK, Byers LA, Gibbons DL, Gay CM, Altan M, Antonoff MB, Le X, Tu J, Saad MB, Pek M, Poh J, Ngeow KC, Tsao A, Cascone T, Negrao MV, Wu J, Blumenschein GR Jr, Heymach JV, Elamin YY. Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA. JTO Clin Res Rep 6(4):100795, 2025. e-Pub 2025. PMID: 40160974.
9. Negrao MV, Paula AG, Molkentine D, Hover L, Nilsson M, Vokes N, Engstrom L, Calinisan A, Briere DM, Waters L, Hallin J, Diao L, Altan M, Blumenschein GR, Skoulidis F, Wang J, Kopetz SE, Hong DS, Gibbons DL, Olson P, Christensen JG, Heymach JV. Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clin Cancer Res 31(6):1069-1081, 2025. e-Pub 2025. PMID: 39804166.
10. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
11. Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
12. Santos LS, MHHDS R, Negrao MV, Goes-Santos BR, Toschi-Dias E, Paixão CJ, Urias U, Giannetti NS, Hajjar LA, Filho RK, Negrão CE. Aerobic Exercise Training Combined with Local Strength Exercise Restores Muscle Blood Flow and Maximal Aerobic Capacity in Long-Term Hodgkin Lymphoma Survivors. Am J Physiol Heart Circ Physiol, 2024. e-Pub 2024. PMID: 38639741.
13. Pan K, Owens J, Elamin Y, Lu C, Routbort M, Zhang J, Fossella F, Negrao MV, Altan M, Pozadzides J, Skoulidis F, Tsao A, Cascone T, Heymach JV, Ostrin E, Le X. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. J Thorac Oncol, 2024. e-Pub 2024. PMID: 38866326.
14. Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol 19(3):500-506, 2024. e-Pub 2024. PMID: 38012986.
15. Han G, Sinjab A, Rahal Z, Lynch AM, Treekitkarnmongkol W, Liu Y, Serrano AG, Feng J, Liang K, Khan K, Lu W, Hernandez SD, Liu Y, Cao X, Dai E, Pei G, Hu J, Abaya C, Gomez-Bolanos LI, Peng F, Chen M, Parra ER, Cascone T, Sepesi B, Moghaddam SJ, Scheet P, Negrao MV, Heymach JV, Li M, Dubinett SM, Stevenson CS, Spira AE, Fujimoto J, Solis LM, Wistuba II, Chen J, Wang L, Kadara H. An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature 627(8004):656-663, 2024. e-Pub 2024. PMID: 38418883.
16. Bernstein E, Luo J, Wang K, Negrao MV, Jänne PA, Sabari JK. Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series. JCO Precis Oncol 8:e2300447, 2024. e-Pub 2024. PMID: 38330263.
17. Rodrigues AG, Sales ARK, Faria D, Fonseca SMR, Bond MMK, Jordão CP, de Souza FR, Bittar CS, Dos Santos MHH, Sarmento AO, Negrao MV, Hajjar LA, Negrão CE, Kalil Filho R. Sympathetic neural overdrive and diminished exercise capacity in reduced ejection fraction heart failure related to anthracycline-based chemotherapy. Am J Physiol Heart Circ Physiol 325(5):H1126-H1132, 2023. e-Pub 2023. PMID: 37682239.
18. Negrao MV, Spira AI, Heist RS, Jänne PA, Pacheco JM, Weiss J, Gadgeel SM, Velastegui K, Yang W, Der-Torossian H, Christensen JG, Sabari JK. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases. J Clin Oncol 41(28):4472-4477, 2023. e-Pub 2023. PMID: 37327468.
19. Vokes NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, Treviño S, Druker V, Qian Y, Patel S, Schmidt S, Hong L, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Negrao MV, Gibbons DL, Vaporciyan A, Le X, Wu J, Zhang J, Rigney U, Iyer S, Dean E, Heymach JV. ATM mutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC. Clin Cancer Res. e-Pub 2023. PMID: 37733794.
20. Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Le X, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer 11(7), 2023. e-Pub 2023. PMID: 37402581.
21. Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
22. Xi Y, Negrao MV, Akagi K, Xiao W, Jiang B, Warner SC, Dunn JD, Wang J, Symer DE, Gillison ML. Noninvasive genomic profiling of somatic mutations in oral cavity cancers. Oral Oncol 140:106372, 2023. e-Pub 2023. PMID: 37004423.
23. Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discov 13(7). e-Pub 2023. PMID: 37068173.
24. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):893-604, 2023. e-Pub 2023. PMID: 36928818.
25. Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun 14(1):695, 2023. e-Pub 2023. PMID: 36755027.
26. Ricciuti B, Alessi JV, Elkrief A, Wang X, Cortellini A, Li YY, Vaz VR, Gupta H, Pecci F, Barrichello A, Lamberti G, Nguyen T, Lindsay J, Sharma B, Felt K, Rodig SJ, Nishino M, Sholl LM, Barbie DA, Negrao MV, Zhang J, Cherniack AD, Heymach JV, Meyerson M, Ambrogio C, Jänne PA, Arbour KC, Pinato DJ, Skoulidis F, Schoenfeld AJ, Awad MM, Luo J. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol 33(10):1029-1040, 2022. e-Pub 2022. PMID: 35872166.
27. Negrao MV, Papadimitrakopoulou VA, Price AC, Tam AL, Furqan M, Laroia ST, Massarelli E, Pacheco J, Heymach JV, Tsao AS, Walker GV, Vora L, Mauro D, Kelley H, Wooldridge JE, Krieg AM, Niu J. Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC. JTO Clin Res Rep 4(3):100423, 2022. e-Pub 2022. PMID: 36925644.
28. Hong L, Lewis WE, Nilsson M, Patel S, Varghese S, Rivera MJ, Du RR, Chen P, Kemp HN, Rinsurongkawong W, Heeke S, Spelman AR, Elamin YY, Negrao MV, Sepesi B, Gibbons DL, Lee JJ, Wu J, Vokes NI, Heymach JV, Zhang J, Le X. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers (Basel) 14(14), 2022. e-Pub 2022. PMID: 35884533.
29. Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40(7):754-767.e6, 2022. e-Pub 2022. PMID: 35820397.
30. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL, Team I. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform 6:e2200040, 2022. e-Pub 2022. PMID: 35944232.
31. Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med 387(2):120-131, 2022. e-Pub 2022. PMID: 35658005.
32. Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, Byun J, Jones J, Anderson AKL, Aparicio A, Tran H, Negrao MV, Zhang J, Wang WL, Wistuba II, Wang J, Wenstrup R, Byers LA, Gay CM. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. Br J Cancer 127(3):569-576, 2022. e-Pub 2022. PMID: 35440668.
33. Shah P, Forget MA, Frank ML, Jiang P, Sakellariou-Thompson D, Federico L, Khairullah R, Neutzler CA, Wistuba I, Chow CB, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth JA, Zhang J, Sepesi B, Gibbons DL, Heymach JV, Haymaker CL, McGrail DJ, Reuben A, Bernatchez C. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer 10(2), 2022. e-Pub 2022. PMID: 35110355.
34. Sepesi B, Zhou N, William WN, Lin HY, Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Negrao MV, Tsao AS, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 164(5):1327-1337, 2022. e-Pub 2022. PMID: 35190177.
35. Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun 12(1):7081, 2021. e-Pub 2021. PMID: 34873156.
36. Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Ann Oncol 33(1):42-56, 2021. e-Pub 2021. PMID: 34653632.
37. Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol 40(7):JCO2101113, 2021. e-Pub 2021. PMID: 34550757.
38. Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34376553.
39. Groehs RV, Negrao MV, Hajjar LA, Jordão CP, Carvalho BP, Toschi-Dias E, Andrade AC, Hodas FP, MJNN A, Sarmento AO, Testa L, Hoff PMG, Negrao CE, Filho RK. Adjuvant Treatment with 5-Fluorouracil and Oxaliplatin Does Not Influence Cardiac Function, Neurovascular Control, and Physical Capacity in Patients with Colon Cancer. Oncologist 26(5):e907, 2021. e-Pub 2021. PMID: 33955124.
40. da Costa TSR, Urias U, Negrao MV, Jordão CP, Passos CS, Gomes-Santos IL, Salemi VMC, Camargo AA, Brum PC, Oliveira EM, Hajjar LA, Chammas R, Filho RK, Negrao CE. Breast Cancer Promotes Cardiac Dysfunction Through Deregulation of Cardiomyocyte Ca2+-Handling Protein Expression That is Not Reversed by Exercise Training. J Am Heart Assoc 10(5):e018076, 2021. e-Pub 2021. PMID: 33619982.
41. Le X, Hong L, Hensel C, Chen R, Kemp H, Coleman N, Ciunci CA, Liu SV, Negrao MV, Yen J, Xia X, Scheuenpflug J, Stroh C, Juraeva D, Tsao A, Hong D, Raymond V, Paik P, Zhang J, Heymach JV. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34957368.
42. Sitthideatphaiboon P, Galan-Cobo A, Negrao MV, Qu X, Poteete A, Zhang F, Liu DD, Lewis WE, Kemp HN, Lewis J, Rinsurongkawong W, Giri U, Lee JJ, Zhang J, Roth JA, Swisher S, Heymach JV. LKB1 mutations in NSCLC are associated with KEAP1/NRF2-dependent radiotherapy resistance targetable by glutaminase inhibition. Clin Cancer Res 27(6):1720-1733, 2020. e-Pub 2020. PMID: 33323404.
43. Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target. J Thorac Oncol 16(4):583-600, 2020. e-Pub 2020. PMID: 33388477.
44. Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S, Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol 21(1):271, 2020. e-Pub 2020. PMID: 33148332.
45. Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets TV, Wang Q, Diao L, Wang J, Federico L, Parra-Cuentas ER, Khairullah R, Behrens C, Correa AM, Gomez D, Little L, Gumbs C, Kadara HN, Fujimoto J, McGrail DJ, Vaporciyan AA, Swisher SG, Walsh G, Antonoff MB, Weissferdt A, Tran H, Roarty E, Haymaker C, Bernatchez C, Zhang J, Futreal PA, Wistuba II, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol 16(1):127-139, 2020. e-Pub 2020. PMID: 33096269.
46. Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, Diao L, Xi Y, Tong P, Shen L, Hofstad M, Kawakami M, Le X, Liu X, Fan Y, Poteete A, Hu L, Negrao MV, Tran H, Dmitrovsky E, Peng D, Gibbons DL, Wang J, Heymach JV. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med 12(559), 2020. e-Pub 2020. PMID: 32878980.
47. Groehs RV, Negrao MV, Hajjar LA, Jordão CP, Carvalho BP, Toschi-Dias E, Andrade AC, Hodas FP, Alves MJ, Sarmento AO, Testa L, Hoff PMG, Negrão CE, Filho RK. Adjuvant treatment with 5-FU and oxaliplatin does not influence cardiac function neurovascular control, and physical capacity in patients with colon cancer. Oncologist. e-Pub 2020. PMID: 32762143.
48. Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ou SH, Gandara DR, Heymach JV, Bivona TG, McCoach CE. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. J Thorac Oncol. e-Pub 2020. PMID: 32540409.
49. Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Wistuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. J Thorac Oncol 15(5):777-791, 2020. e-Pub 2020. PMID: 32068166.
50. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. e-Pub 2020. PMID: 32389639.
51. Corsini EM, Wang J, Wu CC, Fujimoto J, Negrao MV, Chen R, Quek K, Mitchell KG, Chow CB, Little L, Gumbs C, Song X, Behrens C, Correa AM, Antonoff MB, Swisher SG, Heymach JV, Zhang J, Wistuba II, Futreal PA, Sepesi B, Zhang J. Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers. J Thorac Dis 12(5):1952-1959, 2020. e-Pub 2020. PMID: 32642098.
52. Mitchell KG, Diao L, Karpinets T, Negrao MV, Tran HT, Parra ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Dejima H, Francisco-Cruz A, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Haymaker CL, Sepesi B. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32350118.
53. Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 37(3):420, 2020. e-Pub 2020. PMID: 32183953.
54. Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell 36(4):444-457.e7, 2019. e-Pub 2019. PMID: 31588020.
55. Mitchell KG, Negrao MV, Parra ER, Li J, Zhang J, Dejima H, Vaporciyan AA, Swisher SG, Weissferdt A, Antonoff MB, Cascone T, Roarty E, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Sepesi B. Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer. Ann Thorac Surg. e-Pub 2019. PMID: 31550464.
56. Sales ARK, Negrao MV, Testa L, Ferreira-Santos L, Groehs RVR, Carvalho B, Toschi-Dias E, Rocha NG, Laurindo FRM, Debbas V, MUPB R, Mano MS, Hajjar LA, Hoff PMG, Filho RK, Negrão CE. Chemotherapy acutely impairs neurovascular and hemodynamic responses in women with breast cancer. Am J Physiol Heart Circ Physiol 317(7):H1-H12, 2019. e-Pub 2019. PMID: 31002284.
57. Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Lee JJ, Heymach JV, Zhang J. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol 14(6):1021-1031, 2019. e-Pub 2019. PMID: 30780001.
58. Fiorin de Vasconcellos V, Rcc Bonadio R, Avanço G, Negrao MV, Pimenta Riechelmann R. Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status. BMC Palliat Care 18(1):42, 2019. e-Pub 2019. PMID: 31109330.
59. Elamin YY, Gomez DR, Antonoff MB, Robichaux JP, Tran H, Shorter MK, Bohac JM, Negrao MV, Le X, Rinsurogkawong W, Lewis J, Lacerda L, Roarty EB, Swisher SG, Roth JA, Zhang J, Papadimitrakopoulou V, Heymach JV. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC). Clin Lung Cancer 20(1):43-47, 2019. e-Pub 2019. PMID: 30343004.
60. Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clin Cancer Res 24(24):6195-6203, 2018. e-Pub 2018. PMID: 30228210.
61. Girardi DM, de Lima MA, Pereira GCB, Negrao MV, López RVM, Capareli FC, Sabbaga J, Hoff PMG. Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis. BMC Cancer 18(1):378, 2018. e-Pub 2018. PMID: 29614980.
62. Negrao MV, da Silva Rocha LS, da Motta Girardi D, Feher O. Perioperative chemotherapy with and without high-dose methotrexate in adult osteosarcoma. Anticancer Drugs 28(8):915-921, 2017. e-Pub 2017. PMID: 28617714.
63. Knebel FH, Bettoni F, Shimada AK, Cruz M, Alessi JV, Negrao MV, Reis LFL, Katz A, Camargo AA. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC. Lung Cancer 108:238-241, 2017. e-Pub 2017. PMID: 28625643.
64. de Castroneves LA, Negrao MV, de Freitas RM, Papadia C, Lima JV, Fukushima JT, Simão EF, Kulcsar MA, Tavares MR, Jorge AA, de Castro G, Hoff PM, Hoff AO. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis. Thyroid 26(3):414-9, 2016. e-Pub 2016. PMID: 26701095.
65. Caires IQ, Souza KT, Negrao MV, de Oliveira JA, Barroso-Sousa R, de Lima RC, Hoff PM, Diz Mdel P. Definitive chemoradiotherapy for advanced cervical cancer: should it be different in the elderly?. Eur J Obstet Gynecol Reprod Biol 192:86-9, 2015. e-Pub 2015. PMID: 26182837.
66. Souza KT, Negrao MV, da Silva Rocha LS, Di Favero G, da Costa SC, Diz Mdel P. Immature uterine teratoma associated with uterine inversion. Rare Tumors 6(3):5530, 2014. e-Pub 2014. PMID: 25276328.
67. Silva BM, Neves FJ, Negrao MV, Alves CR, Dias RG, Alves GB, Pereira AC, Rondon MU, Krieger JE, Negrão CE, DA Nóbrega AC. Endothelial nitric oxide synthase polymorphisms and adaptation of parasympathetic modulation to exercise training. Med Sci Sports Exerc 43(9):1611-8, 2011. e-Pub 2011. PMID: 21364486.
68. Negrao MV, Alves CR, Alves GB, Pereira AC, Dias RG, Laterza MC, Mota GF, Oliveira EM, Bassaneze V, Krieger JE, Negrao CE, Rondon MU. Exercise training improves muscle vasodilatation in individuals with T786C polymorphism of endothelial nitric oxide synthase gene. Physiol Genomics 42A(1):71-7, 2010. e-Pub 2010. PMID: 20605946.

Invited Articles

1. Negrao MV, Quek K, Zhang J, Sepesi B. TRACERx: Tracking tumor evolution to impact the course of lung cancer. J Thorac Cardiovasc Surg 155(3):1199-1202, 2018. e-Pub 2018. PMID: 29331175.
2. de Castro G, Negrao MV. The Cancer Genome Atlas findings in head and neck cancer: a renewed hope. Curr Opin Oncol 26(3):245-6, 2014. e-Pub 2014. PMID: 24709977.
3. Negrao CE, Negrao MV. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activation of the sympathetic nervous system is the dominant contributor to systemic hypertension. J Appl Physiol (1985) 109(6):2006, 2010. e-Pub 2010. PMID: 21188817.

Review Articles

1. Lim JU, Negrao MV, Hong DS. Optimizing KRAS Therapeutics for Non-Small Cell Lung Cancer. Annu Rev Med, 2025. e-Pub 2025. PMID: 40991960.
2. Planchard D, Sanborn RE, Negrao MV, Vaishnavi A, Smit EF. BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape. NPJ Precis Oncol 8(1):90, 2024. e-Pub 2024. PMID: 38627602.
3. Lee JM, McNamee CJ, Toloza E, Negrao MV, Lin J, Shum E, Cummings AL, Kris MG, Sepesi B, Bara I, Kurtsikidze N, Schulze K, Ngiam C, Chaft JE. Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives. J Thorac Oncol. e-Pub 2023. PMID: 37451404.
4. Negrao MV, Lima JM, Silva SC, Diz MD, da Costa Miranda V. Management of Para-aortic Lymph Node Disease in Patients With Cervical Cancer: What Is the Best Approach?. Int J Gynecol Cancer 27(3):543-549, 2017. e-Pub 2017. PMID: 28107261.

Other Articles

1. Negrao MV, Byers LA, Gay CM Biomarkers May Illuminate the Path Forward for PARP Inhibitors in SCLC. IALSC Lung Cancer News, 2021.
2. Negrao MV Vemurafenib Alone and Combination for Lung Cancer: A Conversation with Marcelo V. Negrao, MD. IALSC Lung Cancer News, 2021.

Abstracts

1. Elamin Y, Gandhi S, Antonoff M, Gibbons D, Negrao MV, Cascone T, Gay CM, Byers LA, Blumenschein G, Rusthoven C, Vaporciyan A, Blakely CM, Gomez D, Feng L, Zhang J, Altan M, Le X, Chang JY, Swisher S, Heymach JV. NorthStar: A phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC). European Society for Medical Oncology Congress 2025, 2025. e-Pub 2025.
2. Negrao MV, Uyeki JV, Cicin I, Chen Y, Shim BY, Yamaguchi M, Burns TF, Sherwood G, Border JN, Shakakibara-Konishi J, Dragnev K, Ammakkanavar NR, Lin VTG, Kim SY, Zhou Y, Fasnacht N, Fink AA, Wildlard MD, Visseren-Grul C, Peters S. Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01. 2025 World Conference on Lung Cancer, 2025. e-Pub 2025.
3. Altan M, Beckham T, Song J, Welsh J, Guha-Thankutra N, Carter B, Blumenschein G, Elamin Y, Tang C, Ghia A, Yeboa D, McAleer MF, Chung C, McGovern SL, Wang C, Martin T, Perni S, Jiang W, De BS, Wefel JS, Wang W, Hicks J, Kim YSB, Weinberg J, Briere TM, Le X, Cascone T, Negrao MV, Skouulidis F, Ferrarotto R, Heymach JV, Li J. Phase I/II Study of Nivolumab and Ipilimumab With Concurrent Stereotactic Radiosurgery for Intracranial Metastases From NSCLC. Barcelona, Spain, 2025. e-Pub 2025.
4. Lee JM, Negrao MV, Cummings A, Shum E, Patil T, Lin J, Shu CA, Saltos A, Florez N, Blakely CM, Sholl L, Saqi A, Ding B, Zhu Q, Schulz K, Grindheim J, Ngiam C, Chaft J. Nautika1: Clinical Outcomes and Pathologic Regression With Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK + NSCLC. 2025 World Conference on Lung Cancer. Barcelona, Spain, 2025. e-Pub 2025.
5. Zhang JJ, Godoy M, Velcheti V, Sterman D, Tam A, Rajaram R, Tran H, Keith R, Heeke S, Chen H, Carter B, Antonoff M, Ostrin E, Le X, Gay C, Negrao MV, Pozadzides JV, Lin SH, Byers L, Vokes N, Cascone T, Gibbons DL, Zhang B, Araujo H, Lu C, Blumenschein G, Rice D, Walsh GL, Chang J, Liao Z, Hofstetter WL, Mehran R, Vaporciyan A, Wistuba I, Wu J, Lee JJ, Heymach JV. IMPRINT-Lung: Single-Arm, Multi-Center Phase II Trial of Immunotherapy With Pembrolizumab for Interception of High-Risk Lung Nodules. 2025 World Conference on Lung Cancer. Barcelona, Spain, 2025. e-Pub 2025.
6. Elamin Y, Gandhi S, Han X, Heeke S, Sui D, Antonoff MB, Gibbons DL, Le X, Negrao MV, Lam VK, Altan M, Tran H, Tu J, Gay CM, Byers L, Cascone T, Blumenschein G, Chang J, Vaporciyan A, Liao Z, Swisher S, Zhang J, Lee J, Wu J, Heymach JV. Final Analysis of Brighstar: LCT With Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC. 2025 World Conference on Lung Cancer. Barcelona, Spain, 2025. e-Pub 2025.
7. Trevino S, Chen H, Halliday A, Ren X, Du R, Hong L, Poteete A, Zhu B, Nilsson M, Aminu M, Rinsurongkawong W, Rinsurongkawong V, Lee J, Blumenschein G, Gay C, Negrao MV, Altan M, Cascone T, Elamin Y, Skoulidis F, Tran H, Anotonott M, Vaporciyan A, Wu J, Kurie J, Gibbons D, Zhang J, Heymach V, Le X, Vokes N. Defining immune and tumor resistant cell states to targeted vs immune etherapy in non-small cell lung cancer ( NSCLC). SITC Annual meeting, 2024. e-Pub 2024.
8. Deboever N, Leung Ch, Lee Y, Mishra A, Federico L, Weissferdt W, Patear A, Dejima H, Francisco-Cruz A, Rojas Alvarez L, Parra E, William N, Reuben A, Kadara H, Wistuba I, Zhang J, Swisher S, Vaporciyan A, Negrao MV, Bernatches Ch, Al-Lazikani B, Jaffray D, Seposi B, Ajami N, Wargo J, Futreal Ph, Tran H, Heymach J, Lin H, Lee J, Gibbons D, Haymaker C, Cascone T, Schmidt S. Integrative machine learning for identifying treatment-specific impacts and Biomarkers applied to multi-platform from non-small-cell lung cancer treated with neoadjuvant chemoimmunotherapies. SITC Annual meeting, 2024. e-Pub 2024.
9. Zhang J, Salehjahromi M, Heeke S, Godoy M, Antonoff M, Carter B, Estrin E, Le X, Negrao MV, Byers L, Lu C, Blumenschein G, Rice D, Walsh G, Rajaram R, Lin S, Hofstetter W, Mehran R, Vaporciyan A, Moghaddam S, Lee JJ, Wu J, Heymach JV. Can-prevent-lung Trial-Canakinumab for the Prevention of Lung Cancer: Updated Interim Clinical and Biomarker Analysis. WCLC Annual Meeting, 2024. e-Pub 2024.
10. Di Federico A, Chen MF, Pagliaro A, Ogliari FR, Stockhammer P, Aldea M, Grant M, DeGiglio A, Alessi JV, Gelsomino F, Negrao MV, Planchard D, Offin MD, Johnson BE. First-line immunotherapy BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer. ESMO Annual Meeting, 2024. e-Pub 2024.
11. Smit E, Anh M-J, Dagogo-Jack I, Felip E, Gelsomino F, Johnson B, Johnson M, Negrao MV, Offin M, Ramalingam S, Sanborn R, Tsao A, Wilner K, Alcasid A, Usari T, Zhang X, Riely G. Updated Safety analysis of Encorafenib Plus Binimetinib in Patients with BRAF V6ooe-MutantMetastatic NSCLC from PHAROS Study. WCLC Annual meeting, 2024. e-Pub 2024.
12. Negrao MV, Molkentine D, Paula AG, Hover L, Nilsson M, Vokes N, Engstrom L, Calinisan A, Briere DM, Waters L, Hallin J, Blumenschein GR, Skoulidis F, Kopetz SE, Hong DS, Gibbons DL, Olsen P, Christensen J, Heymach JV. Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC. 2024 AACR Annual Meeting, 2024. e-Pub 2024.
13. Negrao MV. SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC. 2024 ASCO annual Meeting, Chicago, IL, USA, 2024. e-Pub 2024.
14. Shibata Y, Udagawa H, Nilsson M, Robichaux J, Galan-Cobo A, Negrao MV, Molkentine D, He J, Poteete A, Qian Y, Huang Q, Skoulidis F, Heymach J. The FAK/SRC axis mediates resistance to KRAS G12C inhibitors and its blockade can overcome KRAS inhibitor resistance. 2024 AACR Annual Meeting, 2024. e-Pub 2024.
15. Negrao MV, Cassier PA, Solomon B, Schuler M, Rohrberg K, Cresta S, Dooms C, Tan DSW, Loong H, Amatu A, Assmann K, Fairchild L, Sansregret L, Fan L, Farago AF, Cho BC. KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors. WCLC 2023, 2023. e-Pub 2023.
16. Morelli MP, Negrao MV, Collinson-Pautz MR, Jernigan K, Demars NA, Weitzman A, Adeyemi F, Carpio VH, Jazaeri AA, Johnson B, Pant S, Kebriaei P, Srivastava AK, Deniger DC, Heymach J, Kopetz S. Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study. ASCO Annual Meeting 2023,, 2023. e-Pub 2023.
17. Gay CM, Stewart C, Frumovitz M, Fujimoto J, Xi Y, Wang Q, Wang R, Novegil V, Altan M, Cascone T, Dasari A, Elamin YY, Fossella FV, Glisson BS, Lu CS, Negrao MV, Skoulidis F, Vokes N, Cardnell RJ, Wistuba II, Wang J, Heymach JV, Byers LA. A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas. AACR Annual Meeting 2023, 2023. e-Pub 2023.
18. Cassier PA, Dooms CA, Gazzah A, Felip E, Steeghs N, Rohrberg KS, De Braud FG, Solomon BJ, Schuler MH, Tan DS, Yamamoto N, F Loong HH, Cho BC, Wolf J, Lin C, Negrao MV, Werner L, Cui X, Farago AF, de Miguel MJ. KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC). ASCO Annual Meeting 2023, 2023. e-Pub 2023.
19. Gay CM, Stewart CA, Frumovitz M, Fujimoto J, Xi Y, Wang Q, Wang R, Novegil V, Altan M, Cascone T, Dasari A, Elamin YY, Fossella FV, Glisson BS, Lu CS, Negrao MV, Skoulidis F, Vokes N, Cardnell RJ, Wistuba II, Wang J, Heymach JV, Byers LA. A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas. AACR Annual Meeting, 2023. e-Pub 2023.
20. Aminu M, Vokes NI, Saad MB, Li H, Hong L, Mohamed MS, Boom J, Chen P, Altan M, Gandhi S, Swisher S, Antonoff MB, Pozadzides JV, Blumenschein G, Gibbons DL, Cascone T, Elamin YY, Le X, Negrao MV, Skoulidis F, Tsao AS, Tu J, Lee JJ, Zhang J, Heymach JV, Wu J. Tumor volumetric analysis to correlate disease burden with response to dual immune checkpoint blockade in metastatic NSCLC. AACR Annual Meeting, 2023. e-Pub 2023.
21. Negrao MV, Araujo H, Lamberti G, Cooper AJ, Zhou T, Akhave N, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott S, Bironzo P, Scheffler M, Christopoulos P, Kim SY, Goldberg S, Ni Y, Resuli B, Landi L, S-C T, Nishino M, Owen D, Blakely C, Mountzios G, Shu CA, Bestvina C, Garassino M, Marrone K, Gray J, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil P, Gibbons DL, Meric-Bernstam F, Lee JJ, Herymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC. AACR Annual Meeting, 2023. e-Pub 2023.
22. Hun H, Sinjab A, Treekitkarnmongkol W, Rahal Z, Liu Y, Serrano AG, Feng J, Liang K, Khan K, Lu W, Hernandez S, Cao X, Dai E, Liu Y, Pei G, Hu J, Gomez Bolanos LI, Parra ER, Cascone T, Sepesi B, Moghaddam SJ, Scheet P, Negrao MV, Heymach JV, Li M, Chen J, Dubinett SM, Fujimoto J, Solis LM, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. An atlas of epithelial cell states and plasticity in lung adenocarcinoma. AACR Annual Meeting, 2023. e-Pub 2023.
23. Negrao MV, Wu W, Lindsay CR, Caparica R, Pretre V, Kang Y, Caro N, Farafo A, Ye F, De Castro G. Real-world clinical characteristics and treatment (tx) outcomes by co-mutation status in patients (pts) with KRAS G12C-mutated non-small cell lung cancer (NSCLC). AACR Annual Meeting, 2023. e-Pub 2023.
24. Hong L, Aminu M, Lu X, Saad MB, Chen P, Rinsurongkawong W, Spelamn A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Lee JJ, Roy-Chowdhuri S, Routbort MJ, Heymach JV, Wu J, Zhang J, Vokes NI. Genomic and clinical predictors of early disease progression and chemoimmunotherapy benefit in advanced NSCLC. AACR Annual Meeting, 2023. e-Pub 2023.
25. Negrao MV, Morelli MP, Collinson-Pautz MR, Demars N, Adeyemi F, Carpio VH, Jazaeri AA, Johnson B, Pant S, Kebriaei P, Deniger DC, Heymach JV, Kopetz SE. Objective clinical response by KRAS mutation-specific TCR-T cell therapy in previously treated advanced non-small cell lung cancer. Sixth CRI-ENCI-AACR International Cancer Immunotherapy Conference, New York, 2022. e-Pub 2022.
26. Spira AI, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Velastegui K, Christensen JG, yan X, Anderes KL, Chao RC, Janne PA. KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRAS G12C mutation. ASCO Annual Meeting, 2022. e-Pub 2022.
27. Sabari JK, Spira AI, Heist RS, Janne PA, Pacheco JM, Weiss J, Gadgeel SM, Der-Torossian H, Velastegui K, Kheoh T, Christensen JG, Negrao MV. Activity of adagrasib (MRTX849) in patients with KRAS G12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial. ASCO Annual Meeting, 2022. e-Pub 2022.
28. Elamin YY, Negrao MV, Fossella FV, Byers LA, Zhang J, Gay CM, Tu JC, Pozadzides JV, Tran HT, Lu C, Feng L, Spelman AR, Blumenschein GR, Tsao AS, Heymach J. Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinib-resistant, EGFR-mutant non–small cell lung cancer (NSCLC). ASCO Annual Meeting, 2022. e-Pub 2022.
29. Negrao MV, Morelli MP, Jazaeri AA, Johnson B, Kebriaei P, Deninger D, Groot ED, Collinson-Pautz MR, Demars NA, Holland JS, Heymach J, Baffa R, Kopetz S. First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors. ASCO Annual Meeting, 2022. e-Pub 2022.
30. Le X, Wang R, Vokes N, Elamin Y, Kalhor N, McGrail D, Xi Y, Santiago Treviño III, Hong L, Du R, Blumenschein G, Gay C, Negrao MV, Altan M, Tran H, Hu L, Wang J, Heeke S, Nilsson M, Robichaux J, Dang M, Han G, Byers L, Tsao A, Sepesi B, Bernatchez C, Zhang J, Wang L, Heymach J. 3260 / 2 - Enhanced lineage plasticity in RTK-independent TKI-resistant EGFR-mutant NSCLC. AACR Annual Meeting, 2022. e-Pub 2022.
31. Rocha P, Stewart C, Parra E, Solis LM, Gay CM, Cardnell RJ, Uraoka N, Francisco-Cruz A, Dejima H, Xi Y, Diao L, Wang J, Negrao MV, Zhang J, Wistuba I, Gibbons DL, Byers LA. Multiplex immunofluorescence (mIF) reveals differences in tumor immune microenvironment between molecularly-defined subsets of small cell lung cancer. AACR Annual Meeting, 2021. e-Pub 2021.
32. Lee Y, McGrail D, Tran H, Vasquez ME, Ramos C, Reuben A, Vaporciyan AA, Weissferdt A, Bernatchez C, Cascone T, Wistuba II, Zhang J, Heymach J, Negrao MV, Gibbons DL, Sepesi B, Haymaker CL. Circulating biomarkers are associated with recurrence following complete resection of non-small cell lung cancer. AACR Annual Meeting, 2021. e-Pub 2021.
33. Akhave N, Schmidt S, Reuben A, Cascone T, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget M, McGrail DJ, Weissferdt A, Lin S, Lee Y, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Zhang J, Bristow CA, Negrao MV, Don L. Integrated multi-platform profiling of early-stage non-small cell lung cancer identifies relationship between disease recurrence and decreased native immune response in treatment-naïve resected NSCLC. AACR Annual meeting, 2021. e-Pub 2021.
34. Negrao MV, Schmidt S, Sui D, Sharaf R, Kemp H, Lewis W, Bristow C, Frampton G, Lee J, Heymach J, Gibbons D, Albacker L, Skoulidis F. Genomic Landscape and Clinical Outcomes With Immune Checkpoint Inhibitors in NF1-Mutant NSCLC. World Conference on Lung Cancer, 2021. e-Pub 2021.
35. Elamin YY, Gandhi S, Antonoff M, Mott F, Gibbons DL, Le X, Negrao MV, Sepesi B, Karam JA, Cascone T, Wang L, Blumenschein G, Glisson BS, Tsao AS, Heymach JV. BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC. 2020 ASCO Virtual Scientific Program, 2020. e-Pub 2020.
36. Li J, Wang Y, Tang C, Welsh JW, Guha-Thakurta N, Carter BW, Wefel JC, Ghia AJ, Yeboa D, McAleer MF, Chung C, Woodhouse KD, Elamin YY, Le X, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Altan M. Concurrent nivolumab and ipilimumab with brain stereotactic radiosurgery for brain metastases from non-small cell lung cancer: A phase I trial. 2020 ASCO Virtual Scientific Program, 2020. e-Pub 2020.
37. Negrao MV, Papadimitrakopoulou V, Price AC, Tam AL, Furqan M, Laroia ST, Massarelli E, Pacheco J, Heymach JV, Tsao AS, Walker G, Vora L, Mauro D, Kelley H, Wooldridge JE, Krieg AM, Niu J. TLR9 Agonist CMP-001 Plus Atezolizumab +/- Radiation Therapy in Patients With PD-1 Blockade Resistant Advanced NSCLC. 2020 World Conference on Lung Cancer, 2020. e-Pub 2020.
38. Sales AR, Negrao MV, Testa L, Santos LF, Groehs R, Carvalho B, Dias ET, Rocha N, Laurindo F, Debbas V, Rondon M, Mano M, Hajjar L, Hoff PM, Kalil R, Negrao CE. Chemotherapy acutely impairs neurovascular and hemodynamic responses in patients with breast cancer. Poster Presentation. Experimental Biology Conference, Note: developed the study concept and carried out the study together with Dr Sales, 2019. e-Pub 2019.
39. Gaudreau PO, Negrao MV, Mitchell KG, Corsini EM, Karpinets T, Wang Q, Diao L, Wang J, Federico L, Parra E, Li J, Behrens C, Correa AM, Gomez D, Vaporciyan AA, Weissferdt A, Tran H, Roarty EB, Wistuba II, Reuben A, Haymaker C, Bernatchez C, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL. Neoadjuvant Chemotherapy Is Associated with Immunogenic Cell Death and Increased T Cell Infiltration in Early-Stage NSCLC. Poster Presentation. World Conference on Lung Cancer, 2019. e-Pub 2019.
40. Gaudreau PO, Ajami N, Sepesi B, Karpinets T, Reuben A, Wong M, Parra E, Federico L, Gopalakrishnan V, Mitchell KG, Negrao MV, Spencer C, Vaporciyan AA, Weissferdt A, Haymaker C, Tran H, Bernatchez C, Landry LC, Roarty EB, Cascone T, Heymach JV, Zhang J, Wistuba II, Zhang J, Wargo JA, Gibbons DL. Depicting the Intra-Tumoral Viral and Microbial Landscape of Localized NSCLC Using Standard Next Generation Sequencing Data. Poster Presentation. World Conference on Lung Cancer, 2019. e-Pub 2019.
41. Elamin YY, Robichaux JP, Carter B, Altan M, Gibbons DL, Fossella F, Simon GR, Lam VK, Blumenschein Jr G, Tsao A, Kurie J, Mott FE, Negrao MV, Hu L, He J, Nilsson M, Roeck B, Yang Z, Papadimitrakopoulou VA, Heymach JV. Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC). Oral Presentation. World Conference on Lung Cancer, 2019. e-Pub 2019.
42. Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Hu S, Elamin YY, Le X, Goldberg ME, Wu CJ, Zhang J, Barreto DS, Rinsurongkawong W, Simon GR, Roth J, Swisher S, Lee JJ, Tsao AS, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Miller VA, Alexander BM, Frampton GM, Albacker LA, Shames DS, Zhang J, Heymach JV. BRAF mutations are associated with increased benefit from PD-1/PD-L1 blockade compared with other oncogenic drivers in non-small cell lung cancer. Oral Presentation. World Conference on Lung Cancer,, 2019. e-Pub 2019.
43. Negrao MV, Raymond VM, Lanman RB, Ng PKS, Nagy RJ, Banks KC, Zhu V, Amador BE, Roarty EB, Chae YK, Clarke JM, Crawford J, Ou SI, Gandara DR, Heymach JV, Bivona TG, McCoach CE. Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC. Poster Presentation. ASCO Annual Meeting, 2019. e-Pub 2019.
44. Hong L, Dibaj S, Negrao MV, Reuben A, Roarty EB, Rinsurongkawong W, Lewis J, Gibbons DL, Sepesi B, Papadimitrakopoulou V, Glisson BS, Blumenschein Jr GR, Futreal PA, Wistuba II, Roth JA, Swisher S, Heymach JV, Simon GR, Lee JJ, Zhang J. Spatial and Temporal Heterogeneity of PD-L1 and its Impact on Benefit from Immune Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC). Poster Discussion. ASCO Annual Meeting, Note: led data collection and analysis with Dr Hong, 2019. e-Pub 2019.
45. Mitchell KG, Diao L, Tran HT, Negrao MV, Karpinets T, Wang J, Parra Cuentas ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Vaporciyan AA, Swisher S, Cascone T, Wistuba II, Heymach JV, Zhang J, Gibbons DL, Haymaker CL, Sepesi B. Neutrophilia Is Associated with a Distinct Immunoinhibitory Milieu in Non-Small Cell Lung Cancer. ASCO Annual Meeting, 2019. e-Pub 2019.
46. Negrao MV, Raymond VM, Lanman RB, Ng PKS, Nagy RJ, Banks KC, Zhu V, Amador BE, Roarty EB, Chae YK, Clarke JM, Crawford J, Ou SI, Gandara DR, Heymach JV, Bivona TG, McCoach CE. Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC. Oral Presentation. 4th Annual Young Investigators Forum in Lung Cancer, 2019. e-Pub 2019.
47. Negrao MV, Karpinets T, Li J, Reuben A, Haymaker C, Mitchell KG, Fujimoto J, Chow CW, Parra ER, Federico L, Zhang J, Vaporciyan A, Bernatchez C, Cascone T, Sepesi B, Wistuba II, Heymach JV, Zhang J, Gibbons DL. Immunogenomic profiling identifies a subgroup of squamous cell lung cancers with immunosuppressed tumor microenvironment and correlates TGF-beta and Wnt/beta-catenin signaling as predictive of low PD-L1 expression. Poster Presentation. AACR Annual Meeting, 2019. e-Pub 2019.
48. Le X, Negrao MV, Reuben A, Lee WC, Parra ER, Li J, Karpinets T, Behrens C, Sepesi B, Vaporciyan A, Roth J, Haymaker C, Roarty E, Zhang J, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Heymach JV. Characterization of the tumor immune microenvironment in treatment-naïve EGFR-mutant NSCLC uncovers a low IFN-gamma suppressed immune phenotype. Poster Presentation. AACR Annual Meeting, Note: leading the development of the study concept with Dr Le and data analysis on one of the analyzed cohorts, 2019. e-Pub 2019.
49. Robichaux JP, Nilsson MB, He J, Hu L, Zhang F, Pisegna M, Poteete A, Sun H, Elamin YY, Negrao MV, Raymond V, Lanman, Albacker L, Ahnert JR, Diao L, Wang J, Le X, Bernstam FM, Routbort M, Roeck B, Yang Z, Reddy G, Heymach JV. Pan-cancer analysis of the prevalence and drug sensitivity of HER2 mutations and identification of poziotinib alone or in combination with TDM1 as a pan-HER2 inhibitor. Poster Presentation. AACR Annual Meeting,, 2019. e-Pub 2019.
50. Mitchell KG, Negrao MV, Parra ER, Li J, Reuben A, Vaporciyan AA, Swisher SG, Roth JA, Wistuba II, Bernatchez C, Haymaker C, Futreal PA, Chow CW, Zhang J, Tran H, Vasquez ME, Prado EA, Rodriguez-Canales J, Celestino M, Weissferdt A, Roarty E, Cascone T, Gibbons DL, Heymach JV, Zhang J, Sepesi B, team I. Clinicopathological and immune microenvironment features associated with high tumor mutational burden and PD-L1 expression in resected non-small cell lung cancer. Oral presentation. Society of Thoracic Surgeons 55th Annual, Note: led the genomic data collection for this project, 2019. e-Pub 2019.
51. Le X, Reuben A, Negrao MV, Lee WC, Parra E, Behrens C, Kadara H, Wistuba II, Zhang J, Heymach JV. Characterization of the tumor immune microenvironment in treatment-naïve EGFR-mutant NSCLC uncovers a suppressed immune phenotype. Poster Presentation. 33rd Annual Meeting – Society for Immunotherapy of Cancer (SITC),Note: participated in the development of the study concept and data analysis, 2019. e-Pub 2019.
52. Le X, Puri S, Negrao MV, Nilsson MB, Robichaux JP, Boyle TA, Hicks JK, Roarty E, Rinsurongkawong W, Glisson BS, Zhang J, Papadimitrakopoulou V, Gray JE, Heymach JV. Landscape of EGFR-dependent and independent mechanisms of osimertinib resistance in EGFR-mutant NSCLC patients. Poster presentation. ASCO Annual Meeting, Note: led the clinical data collection and statistical analysis of the study, 2018. e-Pub 2018.
53. Negrao MV, Tang M, Jin, Y, Chen Y, Hu X, Tang H, Xu H, Quek K, Zhang J, Mao X, Song X, Heymach JV, Wistuba II, Byers LA, Glisson BS, Futreal PA, Chen M, Zhang J. Exome sequencing of paired primary and relapsed small cell lung cancers reveals increased copy number aberration complexity to be associated with disease relapse. Poster presentation. AACR Annual Meeting, 2018. e-Pub 2018.
54. Negrao MV, Reuben A, Robichaux JP, Le X, Nilsson M, Elamin YY, Wu CJ, Zhang J, Landry LL, Roarty EB, Rinsurongkawong W, Swisher S, Simon G, Futreal PA, Glisson BS, Zhang J, Heymach JV. EGFR and HER-2 exon 20 mutations are associated with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer. Poster presentation. ASCO Annual Meeting, 2018. e-Pub 2018.
55. Negrao MV, Reuben A, Robichaux JP, Le X, Nilsson M, Elamin YY, Wu CJ, Zhang J, Landry LL, Roarty E, Rinsurongkawong W, Swisher S, Simon GR, Futreal PA, Glisson BS, Zhang J, Heymach JV. Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Poster presentation. World Conference on Lung Cancer, 2018. e-Pub 2018.
56. Negrao MV, Reuben A, Chen R, Sepesi B, Karpinets T, Parra ER, Federico L, Vence LM, Weissferdt A, Tran HT, Vaporciyan AA, Haymaker C, Forget MA, Vasquez ME, Prado EA, Chow CW, Zhang J, Fujimoto J, Roth JA, Meraz IM, Roarty E, Landry LL, Wagner HE, Bogatenkova E, Bernatchez C, Futreal PA, Wistuba II, Swisher S, Heymach JV, Gibbons DL, Zhang J. Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer: Genomic and Immune Profiling Updates from Project ICON. Oral Presentation. World Conference on Lung Cancer, 2018. e-Pub 2018.
57. Heymach JV, Negrao MV, Robichaux JP, Carter BW, Patel A, Altan M, Gibbons DL, Fossella F, Simon GR, Lam VK, Blumenschein GR, Tsao AS, Kurie JM, Mott F, Jenkins D, Mack D, Feng L, Roeck B, Yang Z, Papadimitrakopoulou VA, Elamin YY. A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC). Oral Presentation. World Conference on Lung Cancer, Note: participated in the trial’s data collection, data analysis, and presentation preparation, 2018. e-Pub 2018.
58. Robichaux JP, Elamin YY, Tan Z, Negrao MV, Routbort M, Roeck B, Li S, Liu S, Chen T, Ahnert JR, Diao L, Nilsson MB, Zhang S, Yang Z, Wang J, Bernstam FM, Wong KK, Heymach JV. Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing. Poster presentation. AACR Annual Meeting, Note: led the clinical data collection and statistical analysis of the study, 2018. e-Pub 2018.
59. Le X, Negrao MV, Nilsson M, Robichaux JP, Roarty E, Rinsurongkawong W, Glisson BS, Zhang J, Heymach JV. Mechanisms of resistance for osimertinib for patients with EGFRmutant lung cancer: MD Anderson Cancer Center single institution experience with osimertinib resistance. Oral presentation. AACR Annual Meeting, Note: led the clinical data collection and statistical analysis of the study, 2018. e-Pub 2018.
60. Girardi DM, Pereira GC, Negrao MV, Lima MA, Felizola MM, Fogace RN, Capareli FC, Sabbaga J, Hoff PM. A retrospective study of chemoradiotherapy (CRT) versus chemotherapy (CT) as adjuvant treatment for localized gastric cancer (LGC). Poster Presentation. ESMO Congress, 2016. e-Pub 2016.
61. Rocha LSS, Negrao MV, Girardi DM, Camargo VP, Alban LBV, Hoff PM, Feher O. Perioperative chemotherapy with cisplatin (CP) and doxorubicin (DOX) with and without high-dose methotrexate (HDM) in adult osteosarcoma (AOT): Is methotrexate warranted? – Poster Presentation. ASCO Annual Meeting, 2015. e-Pub 2015.
62. Marques DF, Crosara MAT, Mak MP, Negrao MV, Roitberg FSR, Hoff PM, de Castro G JR. Metastatic lung adenocarcinoma simulating a primary pancreatic tumor: a case report. XVIi Brazilian Clinical Oncology Conference, 2010. e-Pub 2010.
63. Negrao MV, Alves CR, Alves GB, Pereira AC, Dias RG, Laterza MC, Mota GF, Krieger JE, Negrao CE, Rondon MU. Efeitos do Treinamento Fisico no Fluxo Sanguine Muscular em Individuos com Polimorfismo do Gene de ENOS. Oral Presentation - Young Investigator Award. The 30th Cardiology Conference of the Cardiology Society of the State of Sao Paulo, 2009. e-Pub 2009.
64. Negrao MV, Alves CR, Alves GB, Pereira AC, Dias RG, Laterza MC, Mota GF, Krieger JE, Negrao CE, Rondon MU. Efeitos do Treinamento Fisico no Fluxo Sanguine Muscular em Individuos com Polimorfismo do Gene de ENOS. Oral Presentation - "Protasio Lemos da Luz" Basic Science Award Session. The 64th Brazilian Conference of Cardiology, (2009), Salvador, Brazil, 2009. e-Pub 2009.

Book Chapters

1. Elamin YY, Gibbons DL, Negrao MV. Targeted Therapies in Non-Small Cell Lung Cancer. In: Targeted Therapies in Non-Small Cell Lung Cancer. 4th. McGraw-Hill, 2022.
2. Negrao MV, Grativvol RS. Sedation and analgesia. Maria Helena Sampaio Favarato;rafael Saad;Christian Valle Morinaga;Ligia Fidelis Ivanovic;Maria Cecilia Pavanelli;Julio Cesar de Oliveira; Solange Aparcida Petilo de Bricola. In: Manual for the Internal Medicine Resident. First Edition. Editora Manole, v.1,p. 1020-1026, 2015.
3. Matutino AR, Negrao MV, Mark MP. Oncology-Treatment toxicity and management. Milton de Arruda Martins;Flair Jose Carrilho; Venancio Avancini Ferreira Alves;Euclides Ayers de Castillo; Giovanni Guido Cerri. In: Internal Medicine. second edition. Editora Manole, 2015.
4. Dias RG, Alves GB, Negrao MV, Alves CR, Pereira AC. Genetic variants and physical exercise. In: Negrao CE, Barretto ACP (eds) Exercise Cardiology: From Athlete to Cardiomyopathy. Third edition. Editora Manole, v.1, p.333-353, 2010.